"The BAXJECT device is convenient because it eliminates the handling or transfer of filter needles when preparing Factor VIII concentrates for infusion, said Bruce Ewenstein, M.D., global medical director for haemophilia therapy, Baxter BioScience. The whole process is safer and more streamlined, which goes a long way toward building confidence in anyone using the BAXJECT device to prepare haemophilia therapy. The device also is easy and safe enough for children to use, helping them to become more independent in managing their own condition.
Baxter acquired worldwide licensing rights for the use of the BAXJECT device in haemophilia patients in September 2001, a strategic move to further broaden the companys haemophilia franchise.
The BAXJECT device is compatible for use only with Baxter hemophilia therapies and will be introduced globally during the next six months. Initially the BAXJECT device will be available with Recombinate (recombinant antihaemophilic factor) and will eventually replace the transfer needles currently included in all packaging.
A RECOGNIZED NEED
The haemophilia community has asked for safer, faster and more convenient alternatives to preparing Factor VIII, a complicated process that is time-consuming and associated with the risk of needle-stick injury and contamination.
Needle-stick injury is an internationally recognized medical concern. The World Health Organization understands this and advocates that healthcare facilities develop standards, po
Contact: Deborah Spak